Quest PharmaTech Inc.
QPT.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 339.80K | 363.40K | 337.60K | 357.70K | 352.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 515.00K | 564.70K | 571.00K | 588.20K | 590.80K |
| Operating Income | -515.00K | -564.70K | -571.00K | -588.20K | -590.80K |
| Income Before Tax | 3.65M | -54.10K | -805.90K | -152.20K | -1.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.65 | -0.05 | -0.81 | -0.15 | -1.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.65M | -54.10K | -805.90K | -152.20K | -1.28M |
| EBIT | -515.00K | -564.70K | -571.00K | -588.20K | -590.80K |
| EBITDA | -- | -194.50K | -373.60K | -504.30K | -588.60K |
| EPS Basic | 0.02 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.02 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 676.52M | 676.52M | 676.52M | 676.52M | 676.52M |
| Average Diluted Shares Outstanding | 676.52M | 676.52M | 676.52M | 676.52M | 676.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |